I rank all 69 S&P 500 Dividend Aristocrats by my 9F Quality Scores, segmenting them into undervalued, fairly valued, and overvalued groups. My consensus fair value estimates, blending up to 40 data points per stock, highlight 12 undervalued and 18 fairly valued Aristocrats, with 39 currently overvalued. Investment candidates vary by style: ADP, BRO, and NDSN for growth; NEE for total return; PEP and O for income; CAT and GWW for past performance.

BD's 25.5% rally reflects stronger execution, portfolio reshaping, product innovation and U.S. manufacturing investments despite tariffs and cost pressures.

CFS Investment Advisory Services LLC raised its holdings in Becton, Dickinson and Company (NYSE: BDX) by 144.7% during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 6,451 shares of the medical instruments supplier's stock after purchasing an additional 3,815 shares during

Louisbourg Investments Inc. decreased its position in Becton, Dickinson and Company (NYSE: BDX) by 7.0% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 44,940 shares of the medical instruments supplier's stock after selling 3,375 shares during the quarter.

Forbes J M and Co. LLP cut its holdings in shares of Becton, Dickinson and Company (NYSE: BDX) by 86.5% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,901 shares of the medical instruments supplier's stock after selling

Birch Hill Investment Advisors LLC raised its position in Becton, Dickinson and Company (NYSE: BDX) by 862.6% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 21,321 shares of the medical instruments supplier's stock after purchasing an additional 19,106 shares

BDX's Revello stent shows strong nine-month AGILITY trial results, with high vessel patency and low failure rates, boosting its peripheral vascular prospects.

Most income investors chase flashy yields and overlook the quiet compounders that have raised their dividends through recessions, rate shocks, and global pandemics.